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Abstract
Purpose Mitochondrial reactive oxygen species (ROS) production upon reperfusion of ischemic tissue initiates the ischemia/
reperfusion (I/R) injury associated with heart attack. During ischemia, succinate accumulates and its oxidation upon reperfusion
by succinate dehydrogenase (SDH) drives ROS production. Inhibition of succinate accumulation and/or oxidation by
dimethyl malonate (DMM), a cell permeable prodrug of the SDH inhibitor malonate, can decrease I/R injury. However,
DMM is hydrolysed slowly, requiring administration to the heart prior to ischemia, precluding its administration to patients at
the point of reperfusion, for example at the same time as unblocking a coronary artery following a heart attack. To accelerate
malonate delivery, here we developed more rapidly hydrolysable malonate esters.
Methods We synthesised a series of malonate esters and assessed their uptake and hydrolysis by isolated mitochondria, C2C12
cells and inmice in vivo. In addition, we assessed protection against cardiac I/R injury by the esters using an in vivomouse model
of acute myocardial infarction.
Results We found that the diacetoxymethyl malonate diester (MAM) most rapidly delivered large amounts of malonate to cells
in vivo. Furthermore,MAM could inhibit mitochondrial ROS production from succinate oxidation and was protective against I/R
injury in vivo when added at reperfusion.
Conclusions The rapidly hydrolysedmalonate prodrugMAM can protect against cardiac I/R injury in a clinically relevant mouse
model.
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Introduction
Myocardial infarction (MI) is a leading cause of mortality in
the developed world [1, 2]. MIs occur due to a blockage in the
coronary blood supply, rendering the tissue ischemic that leads
on to cardiomyocyte death [2–6]. Rapid reperfusion of the
ischemic myocardium by removing the coronary artery block-
age, typically by primary percutaneous coronary intervention
(PPCI), is the standard of care for MI treatment [5, 6] (Fig. 1a).
However, paradoxically, the reintroduction of oxygen to the
ischemic tissue upon reperfusion causes significant damage to
the heart [4, 7, 8]. This damage is characterised by a burst of
mitochondrial ROS production that initiates the train of events
that leads to cardiomyocyte death by ischemia/reperfusion
(I/R) injury [9–11]. I/R injury is a critical driver for the devel-
opment of post-MI heart failure and as there are no current
therapies, presents a significant unmet need [2, 7, 12, 13].
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Until recently, the mitochondrial ROS production that initi-
ates I/R injury was thought to occur relatively randomly as part
of the chaotic series of events associated with the reperfusion of
ischemic tissue. It is now apparent that during ischemia, the
mitochondrial metabolite succinate accumulates selectively [9,
10, 14]. This rewiring of the citric acid cycle (CAC) occurs in
response to ischemia and the associated purine nucleotide
breakdown. During ischemia, the electrons that accumulate on
NADH in the cytosol reduce oxaloacetate to malate, which is
transported into mitochondria, where it generates fumarate and
NADH [10, 11]. This causes extensive reduction of the mito-
chondrial CoenzymeQ (CoQ) pool which can both drive the
reversal of succinate dehydrogenase (SDH), thereby reducing
fumarate to succinate, and also prevent the oxidation of
succinate generated by the CAC [14]. Succinate accumulation
within tissues, along with purine nucleotide loss, are now seen
as hallmarks of ischemia in a range of tissues and species [10,
15–17]. Upon reperfusion, the reintroduced oxygen rapidly
oxidises the accumulated succinate [10, 18], restoring proton
pumping by respiratory complexes III and IV. This generates a
highly reduced CoQ pool and a large proton motive force (Δp)
across the mitochondrial inner membrane which is close to
maximal because the low levels of ADP curtail its consumption
by ATP synthesis [17, 19]. Together, these drive the production
of ROS by reverse electron transport (RET) through complex I
[10, 20] (Fig. 1b). RET seems to be the principal source of the
ROS burst during the first minutes of reperfusion that initiates I/
R injury in MI [10, 11, 21].
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patients undergoing PPCI. b
During ischemia, succinate accu-
mulates. Upon reperfusion, suc-
cinate is rapidly oxidised by SDH
allowing proton pumping from
complex III and IV, maintaining
the highly reduced CoQ pool and
generating a large Δp, thus driv-
ing electrons through complex I
by RET. RET transfers electrons
to oxygen, generating superoxide
initiating the oxidative damage in
I/R injury. c Malonate prodrugs
could be administered during
PPCI where they would enter
cells, hydrolyse to release
malonate and go on to inhibit
SDH in mitochondria
Cardiovasc Drugs Ther
Due to its essential role in I/R injury, therapeutic strategies
targeting both succinate accumulation and/or its oxidation
have potential [21, 22]. This is supported by the efficacy of
the cell-permeable dimethyl malonate (DMM). DMM is a
prodrug of the SDH competitive inhibitor malonate which
prevents both succinate accumulation and oxidation, and
thereby decreases cardiac I/R injury [10, 17, 23]. As malonate
is both a reversible inhibitor of SDH and an endogenous mol-
ecule that is readily metabolised, it has excellent therapeutic
attributes. However, to be clinically effective in treating MI,
the malonate prodrug must be administered upon reperfusion
during PPCI (Fig. 1a) and be both taken up and hydrolysed to
malonate within a few minutes (Fig. 1c). Whilst the disodium
salt of malonate itself has shown to be cardioprotective in a
large animal model, the mechanism of uptake into
cardiomyocytes is unclear and the requirement to use high
concentrations injected intracoronary may limit its use [15].
At physiological pH, malonate is largely in its dianionic form
(pKa1 = 2.83, pKa2 = 5.69 [24]); therefore, the proportion of
neutral malonate, capable of diffusion across biological mem-
branes, is negligible at physiological pH (< 0.003% at pH 7.4).
Thus, the unmediated diffusion of malonate across biological
membranes is low. Therefore, to enhance the acute delivery of
malonate to the heart during PPCI, we set out to assess a series
of malonate esters, thereby masking the charged moieties and
creating a neutral and membrane permeable malonate prodrug
[25]. The malonate prodrugs would subsequently be hydro-
lysed in the cell to release malonate rapidly in vivo, to inhibit
SDH activity and prevent I/R injury (Fig. 1c).
Materials and Methods
Chemical Syntheses
The fluorinated esters ditrifluoroethyl malonate (MTF) and
dihexafluoropropyl malonate (MHF) were synthesised by re-
action of malonyl chloride with excess trifluoroethanol or
1,1,1,3,3,3-hexafluoro-2-propanol , respect ively .
Diacetoxymethyl malonate (MAM) was prepared by
O-alkylation of malonate with acetoxymethyl bromide fol-
lowing the procedure of Bao et al. [26]. The details of the
chemical syntheses are described in the “Electronic
Supplementary Material” section.
Maintenance of Cells in Culture
C2C12 (murine) and HeLa (human) cells were obtained from
American Type Culture Collection (ATCC). Both were main-
tained at 37 °C, 5% CO2 and 100% humidity. Cell media was
changed every 2–3 days with passaging at < 80% confluency
and seeding at no higher than 5 × 103 viable cells/cm2 with a
typical subcultivation ratio of 1:5–1:10. Cell media was
DMEM media (4.5 g/l glucose, 1 mM sodium pyruvate,
2 mM Glutamax, 1.5 g/l sodium bicarbonate) with 10%
Foetal Bovine Serum (FBS), 100 U/ml penicillin and
100 mg/ml streptomycin.
Animals
Procedures were carried out in accordance with the UK
Animals (Scientific Procedures) Act of 1986 and the
University of Cambridge Animal Welfare Policy under pro-
ject licence 70/8238 and 70/7963, reviewed by the University
of Cambridge Animal Welfare Ethical Review Board or the
Tianjin Medical University Animal Care and Use Committee.
All animal experiments described were carried out in accor-
dance with the Guide for the Care and Use of Laboratory
Animals, published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996). Wistar rats (fe-
male, 10–12 weeks) and C57BL/6 J mice (male, 8–12 weeks)
were ordered from Charles River Laboratories UK (Margate,
UK) or the Institute of Laboratory Animal Science, Chinese
Academy of Medical Sciences (Beijing, China). Both were
maintained with ad libitum chow and water.
LC-MS/MS Analysis of Malonate and Succinate
LC-MS/MS analysis of malonate and succinate was per-
formed using an LCMS-8060 mass spectrometer (Shimadzu,
UK) with a Nexera UHPLC system (Shimadzu, UK). Samples
were stored in a refrigerated autosampler (4 °C) upon injection
of 5 μl into a 15 μl flowthrough needle. Separation was
achieved using a SeQuant ZIC-HILIC column (3.5 μm,
100 Å, 150 × 2.1 mm, 30 °C column temperature; Merck
Millipore, UK) with a ZIC-HILIC guard column (200 Å,
1 × 5 mm). A flow rate of 200 μl/min was used with mobile
phases of: A) 10 mM ammonium bicarbonate (pH un-
changed); and B) 100% acetonitrile. A gradient of 0–
0.1 min, 80% MS buffer B; 0.1–4 min, 80–20% B; 4–
10 min, 20% B; 10–11 min, 20–80% B; and 11–15 min,
80% B was used. The mass spectrometer was operated in
negative ion mode with multiple reaction monitoring
(MRM), and spectra were acquired using the LabSolutions
software (Shimadzu, UK), with compound quantities calculat-
ed from relevant standard curves in MS extraction buffer
(50% (v/v) methanol, 30% (v/v) acetonitrile, 20% (v/v) MS-
grade water) compared with 1 nmol of relevant internal stan-
dard either [13C3]-malonate or [
13C4]-succinate for malonate
and succinate, respectively (Supplementary Fig. 1).
Hydrolysis of Malonate Esters
Malonate esters (200 μM) were incubated in KCl buffer
(120 mM KCl, 10 mM HEPES, 1 mM EGTA pH 7.2 or 8,
37 °C)pH 7.2 or 8, 37 °C) alone or KCl buffer supplemented
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with porcine liver esterase (1 mg protein/ml; pH 7.2, 37 °C;
PLE) on a heated shaking block (37 °C, 1000 rpm)1. Aliquots
of 20 μl were taken at time points of 0, 15, 30 min, 1, 2 and
4 h. Additional time points were taken in PLE-free incuba-
tions, at 8 and 24 h. Samples were extracted in 750 μl MS
extraction buffer containing MS internal standard (1 nmol)
and analysed by LC-MS/MS. Importantly, controls showed
that there was no hydrolysis of these esters when directly
analysed by LC-MS/MS, thus malonate release was solely
from hydrolysis under the incubation conditions (data not
shown).
Isolation of Rat Heart Mitochondria
Rat heart mitochondria (RHM) were isolated as described
previously [27]. Briefly, rats were culled by cervical disloca-
tion in accordance with local procedures; the heart rapidly
excised and washed with STEB buffer (250 mM sucrose,
5 mM Tris-Cl, 1 mM EGTA, 0.1% (w/v) BSA; pH 7.4,
4 °C) and minced finely. The minced tissue was homogenised
in a dounce homogeniser in the buffer and centrifuged
(1000 ×g, 5 min, 4 °C). The resulting supernatant was filtered
through pre-wet muslin and centrifuged to pellet mitochondria
(10,000 ×g, 10 min, 4 °C). The mitochondrial pellet was re-
suspended in buffer and re-centrifuged under the same condi-
tions to pellet mitochondria. The final mitochondrial pellet for
all tissues was resuspended in STE buffer (no BSA) and
assayed for protein concentration by BCA assay (Thermo
Fisher Scientific, UK).
Preparation of Bovine Heart Mitochondrial
Membranes
Bovine heart mitochondria (BHMMs) were isolated by differ-
ential centrifugation similarly to rat heart mitochondria and as
described previously [28]. To prepare (BHMMs), bovine
heart mitochondria were blended with MilliQ water (4 °C)
before adding KCl (150 mM final concentration) and continu-
ing to blend until homogeneous. The suspension was centri-
fuged (13,500 ×g, 40 min, 4 °C), the supernatant discarded
and the pellet homogenised in resuspension buffer (20 mM
Tris-Cl, 1 mM EDTA, 10% glycerol, pH 7.55 at 4 °C) before
snap freezing membranes and storing at − 80 °C until use. The
protein concentration of the membranes was determined by
BCA assay (Thermo Fisher Scientific, UK).
Complex II + III Activity Assay
BHMMs (80 μg protein/ml) were incubated in potassium
phosphate buffer (50 mM potassium phosphate, 1 mM
EDTA, pH 7.4, 4 °C) supplemented with KCN (3 mM), rote-
none (4 μg/ml) and succinate (as indicated). In a 96-well mi-
croplate, malonate or vehicle control and membrane
incubations were plated and incubated (10 min, 30 °C).
Oxidised cytochrome c was added prior to measuring respira-
tory chain activity by following the reduction of cytochrome c
spectrophotometrically at 550 nm (20-s intervals for 5 min,
30 °C; Spectramax Plus 384, Molecular Devices, UK). Final
concentrations of bovine heart mitochondrial membranes
(10 μg protein/well), cytochrome c (30 μM) and succinate
(either 0.2, 1 or 5 mM) were used. Control complex II+III
activity with 200 µM, 1 mM or 5 mM succinate was 154.6
± 3.7, 268.2 ± 4.6, 345.9 ± 8.7 nmol Cyt c reduced/min/mg
protein, respectively.
Malonate Delivery to Mitochondria
Isolated mitochondria (0.5 mg protein/ml) were incubated in
KCl buffer (pH 7.4; 37 °C) supplemented with glutamate
(1 mM) and malate (1 mM) and dipotassium malonate or
malonate esters (200 μM) for 5 min before pelleting mito-
chondria (10,000×g, 5 min, 4 °C), rinsing the tube without
disturbing the pellet before drying the pellet by aspirating
and blotting residual liquid with tissue paper. Pellets were
extracted with MS extraction buffer containing MS internal
standard and analysed by LC-MS/MS. To calculate the oc-
cluded malonate in the mitochondrial pellet that was not with-
in the mitochondria (for dipotassisum malonate incubations),
we used a value obtained earlier in our lab for the non-
mitochondrial volume determined by comparing the [14C]-su-
crose and H2O volumes of the pellet [29]. This value was
8.1 μl/mg protein. The concentration of malonate within the
mitochondria was calculated using a mitochondrial volume of
0.6 μl/mg protein [29].
Measurement of ROS Production by RET
ROS production by RET in isolated heart mitochondria was
measured by following the conversion of Amplex Red to
resorufin as described previously [27]. Briefly, in a 96-well
plate, isolated RHM were incubated in 150 μl KCl buffer
(pH 7.2, 37 °C) supplemented with Amplex Red
(Invitrogen, Thermo Fisher Scientific), horseradish peroxi-
dase, BSA, superoxide dismutase and either malonate,
malonate diesters or vehicle control. To initiate RET, 50 μl
KCl supplemented with succinate was added to each well and
the plate read using a fluorometric plate reader (SpectraMax
Gemini XS; Molecular Devices) at 37 °C. Resorufin fluores-
cence was detected by λex = 570 nm and λem = 585 and cali-
brated against known concentrations of hydrogen peroxide
(46.6 M−1 cm−1 at 240 nm). The final concentrations in the
assay were as follows: RHM (70 μg protein/well), Amplex
Red (12.5 μM), horseradish peroxidase (20 μg/ml), BSA
(200 μg/ml), superoxide dismutase (40 μg/ml), malonate (0–
5 mM), malonate diesters (250 μM) and succinate (0–5 mM
or 5 mM when used with malonate diesters).
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Incubation of Cells with Malonate Diesters
C2C12 or HeLa cells were plated in 6-well plates (300,000
cells/well) and adhered overnight. The following day, the me-
dium was replaced with Krebs buffer (116 mMNaCl, 4.7 mM
KCl 1.2 mMMgSO4.7H2O, 25 mMNaHCO3 1.4 mMCaCl2,
11 mM glucose; pH 7.4, 37 °C) containing malonate diesters
or 0.1% DMSO (control) and incubated for 15–240 min at
37 °C prior to extracting. Parallel plates were incubated under
the same conditions and used to measure protein levels by
BCA assay (Thermo Fisher Scientific, UK). After incubation,
cells and supernatant were extracted for LC-MS/MS. The su-
pernatant was removed and centrifuged (17,000× g, 10 min,
4 °C) before adding 50 μl of the resulting supernatant to
750 μl MS extraction buffer containing MS internal standard.
Cells were washed 4 times with ice-cold PBS before 500 μl
MS extraction buffer containing MS internal standard was
added to each well and incubated for 15 min on dry ice.
Cells were scraped into microcentrifuge tubes and together
with the supernatant samples were agitated (1200 rpm,
15 min, 4 °C) before incubating at − 20 °C for 1 h. Samples
were centrifuged (17,000 ×g, 10 min, 4 °C); the supernatant
transferred to a fresh tube and recentrifuged under the same
conditions. The resulting supernatant was transferred to pre-
cooled MS vials and analysed by LC-MS/MS.
In Vivo Delivery of Malonate Diesters
DMM, MAM or MTF (160 mg/kg) were administered to
C57BL/6 J mice via a 100 μl tail vein bolus injection in
0.9% saline + 0.1% DMSO. Mice were culled either 5, 20 or
40 min after injection, organs harvested and snap frozen in
liquid nitrogen. Malonate was extracted from tissues by
homogenising tissue (40 mg wet weight/ml) in MS extraction
buffer containingMS internal standard in a Precellys 24 tissue
lyser (6500 rpm, 15 s × 2; Bertin Instruments, France) using
CK-28R homogenising tubes (Bertin Instruments, France),
then the homogenised samples were incubated (− 20 °C,
1 h). Samples were centrifuged (17,000 ×g, 10 min, 4 °C);
the supernatant transferred to a fresh tube and recentrifuged
under the same conditions. The resulting supernatant was
transferred to pre-cooled MS vials and analysed by LC-MS/
MS.
In Vivo Left Anterior, Descending Coronary Artery
(LAD) Occlusion Murine Myocardial Infarction Model
The left anterior descending (LAD) coronary artery was ligat-
ed to induce MI in an open chest, in situ mouse model as
previously described, to assess the effects of compounds on
I/R injury [30]. Briefly, mice were anesthetised by adminis-
tration of sodium pentobarbital (70 mg/kg intraperitoneally),
endotracheally intubated, ventilated with 3 cm H2O positive
end expiratory pressure and kept at 37 °C using a rectal
thermometer-controlled heatpad (TCAT-2LV, Physitemp,
USA). Ventilation frequency was maintained at 110 breaths/
min, with tidal volume between 125 and 150μl. The heart was
exposed and a suture was placed around the prominent branch
of the LAD and passed through a small plastic tube used to
initiate ischemia by pressing the tube against the heart surface
to occlude the LAD. Mice were subjected to 30 min of ische-
mia and 120 min of reperfusion; after reperfusion, hearts were
stained with Evans Blue and 2% triphenyltetrazolium chloride
(TTC) and blindly analysed by an independent researcher.
Statistical Analysis, Randomisation and Blinding
All data in figures are presented as mean ± S.E.M., unless
stated otherwise in the figure legend. Statistical analysis was
performed using either one or two-way ANOVA with the
suitable post hoc correction for multiple comparisons de-
scribed in the figure legend. A p value of less than 0.05 was
considered significant. Statistics were calculated in the Prism
8.0 software (GraphPad Software Inc., USA). Randomisation
and blinding were carried out where possible: mass spectrom-
etry samples were randomised and analysed blindly; infarct
size measurements were carried out in a randomised and
blinded fashion by independent investigators.
Results
DMM Is Not Cardioprotective when Administered at
Reperfusion
Whilst DMM has shown protection against cardiac I/R injury
when administered prior to ischemia [10, 23], its protective
effect when infused at reperfusion is unknown. As adminis-
tration of DMM at reperfusion is more clinically relevant for
myocardial infarction patients undergoing PPCI, we first de-
termined cardioprotection by DMMwhen given before ische-
mia against DMM administration at reperfusion. This was
done by measuring infarct size in the in vivo LAD mouse
model of acute myocardial infarction. DMM conferred con-
siderable cardioprotection when the infusion began shortly
before ischemia but was not protective when administered
prior to reperfusion (Fig. 2a and Supplementary Fig. 2). To
confirm whether this was due to differences in malonate de-
livery, we measured the levels of malonate in the at-risk tissue
and found that the levels of malonate were significantly ele-
vated when DMM was administered prior to and during is-
chemia, but not when given immediately before reperfusion
(Fig. 2b). The levels of succinate measured at 1 min reperfu-
sion were also significantly lower when DMM was infused
prior to and during ischemia (Fig. 2c). This suggests that the
malonate released from DMM during ischemia decreases the
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accumulation of succinate during ischemia, as shown previ-
ously [10]. If malonate is administered on reperfusion, it
would be expected to block succinate oxidation, leading to
an elevation in succinate; however, the succinate levels when
DMM was infused at reperfusion were not different from sa-
line infused hearts (Fig. 2c). This suggested that the release of
malonate from DMM was too slow to be protective when
administered upon reperfusion.
Development of Rapidly Cleaved Malonate Prodrugs
We next designed and assessed nine further malonate ester
prodrugs with the goal of accelerating malonate delivery
in vivo. Two approaches were taken to improve malonate
delivery—either increasing the hydrophobicity of the mole-
cule to enhance diffusion across biological membranes or cre-
ating esters which are hydrolysed faster by cellular esterases.
A range of ester chain lengths with differing hydrophobicities
were introduced, and the branched chain tert-butyl group was
included as an ester resistant to enzymatic hydrolysis [31, 32].
To release malonate faster (referred to as tuned malonate es-
ters), a preferential esterase substrate in the form of
acetoxymethyl (diacetoxymethyl malonate; MAM) or elec-
tron withdrawing, fluorine-containing groups (ditrifluoroethyl
malonate; MTF, and dihexafluoropropyl malonate; MHF)
were introduced. The compounds are shown in Fig. 3a and
their calculated octanol:water partition coefficients (CLogP)
are shown in Fig. 3b. Their syntheses are described in the
“Electronic Supplementary Material” section.
Tuned Malonate Esters Rapidly Release Malonate
We first measured malonate release by spontaneous hydroly-
sis of the esters at the pH of the cytosol (7.2; Fig. 4a) and at the
pH of the mitochondrial matrix (8; Fig. 4b). As expected, the
esters with electron-withdrawing substituents (MHF, MAM
and MTF) released malonate far more rapidly than DMM
and this release was faster at pH 8 (Fig. 4 a and b) [33, 34].
This is consistent with both the BAc2 and the E1CB base-
catalysed hydrolysis mechanisms that are possible [35]. To
facilitate comparison of the relative hydrolysis rates of these
esters, we calculated half-lives, based on malonate production
which requires hydrolysis of both ester bonds in the diesters.
This approach conflates two hydrolysis rates, with that for
lysis of the ester bond of intermediate monoesters expected
to be slower due to their negative charge. Most malonate es-
ters were relatively stable under non-enzymatic conditions
with half-lives exceeding 24 h at pH 7.2. Unsurprisingly, the
electron-rich dialkyl esters hydrolysed most slowly with the
half-life shortest for DMM and the longest for DBM,
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reflecting the anticipated steric properties of the side chains
and their propensity to impact hydrolysis (Fig. 4c) [33].
Despite their increased lability, the electron poor malonate
esters (MHF, MAM and MTF) were relatively stable under
non-enzymatic conditions at pH 7.2: MTF’s half-life
exceeded 24 h and that of MAM was ~ 19 h, but MHF’s
half-life was modest at only 3.5 h (Fig. 4c). Thus, with the
possible exception of MHF, all the esters are stable enough to
survive in the circulation at physiological pH values for the
time required for suitable cardiac intervention.
Within the cell, the expectation is that these esters will be
hydrolysed by intracellular esterases. To assess this, we used
porcine liver esterase (PLE), which is widely used as a model
enzyme for in vivo ester hydrolysis [36–39]. As expected, all
the tuned esters released malonate far more rapidly when in-
cubated in the presence of PLE (Fig. 4d). The rate enhance-
ment at pH 7.2 caused by PLE is shown in Fig. 4c. This
analysis reveals that PLE enhanced the hydrolysis of most of
the malonate esters between ~ 4–1500-fold. However, for
DBM, there was no enhancement due to the steric hindrance
of the tert-butyl groups. For MHF, the enhancement was only
4.7, due to rapid spontaneous hydrolysis and the limited effect
on rate of electron withdrawing groups on the alkoxy substit-
uent because the rate determining step in PLE is after
transesterification to the enzyme [34]. The similar rate en-
hancement for MTF is consistent with this. Finally, we plotted
the enzymatic rate of hydrolysis of these esters against their
hydrophobicity (Fig. 4 e and f). This indicated that for straight
chain, unfluorinated dialkyl esters increased hydrophobicity
correlated with increased susceptibility to enzymatic
hydrolysis.
Overall, these data confirmed that malonate release from
DMM is occurring too slowly to be cardioprotective when
administered at reperfusion. It also showed potential candidate
compounds for further testing with enhanced hydrolysis (e.g.
MAM) or with both enhanced hydrolysis and hydrophobicity
(MHF and MTF).
Malonate Ester Prodrugs Deliver Malonate to
Mitochondria
We next estimated the concentration of malonate required
within the ischemic tissue to prevent ROS production by
succinate-driven RET. As malonate is a competitive inhibitor
of SDH, the concentration required will also depend on that of
succinate, which is between 1.5 and 3 mM in the ischemic
mouse heart at the onset of reperfusion [40]. For mitochondri-
al membranes respiring on 5 mM succinate, ~ 50 μM
malonate was required to inhibit SDH activity by 50% (Fig.
5a). In isolated heart mitochondria respiring on 5 mM succi-
nate, ~ 450 μMmalonate was required to inhibit by 50% ROS
production by RET (Fig. 5b). The higher concentration re-
quired in isolated mitochondria likely reflects the requirement
for transport of malonate into the matrix. As similar transport
will be required within the tissue, this suggests that a target
concentration of ~ 0.5 mM malonate within the cytosol is
required to achieve a significant decrease in ROS production
by SDH inhibition. Considering the intracellular water vol-
ume of a rodent heart is ~ 615 μl/g wet weight tissue [41], this
suggests a target tissue malonate level to be ~ 0.3 nmol/mg
wet weight.
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The intended target of malonate for amelioration of I/R
injury is SDH within mitochondria. Therefore, the han-
dling of the malonate prodrug by the cell could occur in
two ways—either hydrolysis and release of malonate
within the cytosol or diffusion into mitochondria and re-
lease there (Fig. 5c). To see if malonate released in the
cytosol by hydrolysis of the prodrugs would be rapidly
transported into mitochondria, subsequently inhibiting
SDH, we incubated mitochondria with malonate for
5 min and showed that this led to extensive uptake into
mitochondria (Fig. 5d).
Thus, generating malonate in the cytosol is sufficient to
deliver it to the mitochondria in the cell. To test whether
malonate esters could be hydrolysed within mitochondria to
deliver malonate directly, we incubated rat heart mitochondria
with malonate esters and found that malonate was delivered to
mitochondria by the malonate ester prodrugs (Fig. 5e). As
there is negligible spontaneous hydrolysis of these esters over
5 min (Fig. 4a), this is all due to hydrolysis of the ester within
the mitochondrial matrix. MAM delivered significantly more
malonate to mitochondria than the other malonate ester
prodrugs and was far more effective at doing so than DMM.
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The improved malonate ester prodrugs also reduced ROS pro-
duction by succinate-driven RET in heart mitochondria (Fig.
5f). Whilst MHF reduced ROS production more than MAM,
less malonate was detected in the mitochondria, suggesting
that this difference is not through SDH inhibition, rather other
effects such as off-target inhibition or mitochondrial toxicity.
Malonate Ester Prodrugs Improve Cellular Malonate
Delivery
To see if these malonate ester prodrugs have the potential to
rapidly release malonate within cells, we incubated them with
cell lines over time and compared malonate generation with
that of DMM. C2C12 mouse myoblasts were incubated with
the malonate diesters and the malonate and succinate levels in
the cell pellet and extracellular supernatant measured by LC-
MS/MS. We found that incubation with MAM delivered con-
siderably more malonate (> 20-fold) to the cell than any other
compound (Fig. 6a and Supplementary Fig. 3) and delivered
> 100-fold more malonate to the cell than DMM. The
malonate esters released more malonate in the supernatant
than the non-enzymatic hydrolysis incubations, suggesting
that some malonate produced intracellularly could leave the
cell (Supplementary Fig. 4a). The decrease in malonate in the
cell over time likely reflects the endogenous metabolism of
the compound. Malonate is readily conjugated to CoA using
ATP by acyl-CoA synthetase family member 3 (ACSF3) in
mitochondria [42]. Malonyl-CoA is subsequently
decarboxylated by malonyl-CoA decarboxylase (MLCYD)
to acetyl-CoA, and as this enzyme has both mitochondrial
and cytosolic isoforms [43, 44], malonate can be readily
metabolised. Thus, despite achieving high malonate levels in
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the cell and inhibiting SDH initially, it is rapidly metabolised
by endogenous pathways, enabling SDH activity to resume.
Interestingly, cellular succinate levels were also significantly
elevated in MAM treated cells (Fig. 6b), confirming mitochon-
drial delivery of malonate and inhibition of SDH. Here, the
malonate delivered by MAM inhibits SDH, preventing the ox-
idation of succinate and leading to its extensive accumulation
and transport out of the cell (Supplementary Fig. 4b). Succinate
levels in DMM treated cells were not significantly different
from control cells, suggesting that the levels of malonate
achieved here are low. Importantly, similar results were seen
in different cell types, and also when FBS was included in the
incubations, despite its esterase activity and protein binding,
which mimics that of the blood stream (Supplementary Fig.
5) [45, 46]. As MAM achieved the best delivery of malonate
in cells, with acceptable cellular toxicity, as measured by LDH
release (Supplementary Fig. 6), it was taken forward to assess
in vivo malonate delivery and compared against DMM.
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MAM Delivers Malonate Rapidly to the Heart
To test the delivery of malonate in tissues in vivo, C57BL/6 J
mice were tail vein injected with a bolus of either DMM,
MAM or MTF (160 mg/kg in 100 μl) and the malonate levels
in the heart assessed (Fig. 6c). MAM delivered significantly
more malonate to the myocardium than DMM orMTF, which
was also rapidly lost from the heart over time presumably due
to metabolism to malonyl-CoA (Fig. 6c). The kinetics of
malonate delivery to the heart by MAM suggest a useful pro-
file for the prevention of cardiac I/R injury, whereby a tran-
sient inhibition of SDH is achieved during early reperfusion
but with subsequent restoration of normal mitochondrial
function.
MAM Is Cardioprotective when Administered at
Reperfusion
We next tested the cardioprotective effect of MAM in a mu-
rine left anterior descending (LAD) coronary artery occlusion
model of MI, whereby the artery is occluded for 30 min and
subsequently reperfused with or without an intervention (Fig.
6d). Whilst 160 mg/kg of MAM was toxic to the animals
undergoing the LAD model (data not shown, we note there
was no obvious distress to the animals prior to sudden death
which suggested that the toxicity was not due to MAM break-
down products directly but was a complicated interaction with
anesthesia), administration of either a 10- or 100-fold lower
dose (16 or 1.6 mg/kg) of MAM during early reperfusion was
significantly cardioprotective compared with relevant control
animals and to DMM at the higher dose (Fig. 6d, e).
Therefore, by developing a rapidly cleaved malonate ester,
wewere able to deliver sufficient malonate when administered
at reperfusion to inhibit SDH, slow down the oxidation of
succinate and prevent ROS production by RET.
Discussion
DMM has been extensively used as a cell permeable SDH
inhibitor, particularly in elucidating the mechanism of succi-
nate’s involvement in I/R injury. Whilst preventing succinate
accumulation with DMM is protective, clinically relevant
agents for MI are limited to being administered concurrent
to reperfusion. DMM hydrolysed slowly in the in vitro setting
and thus confirmed why DMM was not protective when ad-
ministered at reperfusion. By developing more rapidly hydro-
lysed malonate esters, these were able to deliver far more
malonate to cells and in vivo, with MAM the most effective.
The two approaches taken to improve malonate delivery
suggest that both drug hydrophobicity and rate of hydrolysis
were important. As longer dialkyl esters could also deliver
more malonate than DMM, it is likely that the favourable
diffusion across the hydrophobic biological membranes led
to increased potential for hydrolysis and subsequent intracel-
lular malonate delivery. In addition, as MAM was both as
hydrophobic as, and more rapidly hydrolysed than, DMM,
this combination of molecular properties was clearly
favourable for the delivery of small molecule dicarboxylates
to the cell. This screening process also highlights the impor-
tance of careful prodrug ester selection, as this is critical for
the development and efficacy of the intended compound.
The kinetics of malonate release from MAM may also be
highly advantageous as an intervention for I/R injury.
Malonate is released very rapidly into the heart tissue in the
first minutes after administration of MAM, inhibiting SDH
and preventing the pathological production of ROS during
reperfusion. Whilst SDH is inhibited by malonate, normal
mitochondrial function would resume and the ATP/ADP ratio
restored. Malonate is subsequently metabolised, releasing the
block on SDH and thus providing a transient effect during the
therapeutic window. This action of MAM would minimize
drug exposure and continual inhibition, thus reducing the pos-
sibility of off target and deleterious effects.
The cardioprotective effect of MAM further confirms the
role of SDH as a critical enzyme in the pathology associated
with I/R injury. We have now shown that targeting SDH either
before ischemia using DMM or at reperfusion using MAM
leads to a reduction in infarct size upon reperfusion. Both ap-
proaches alter the metabolism of succinate, either its production
or oxidation by SDH, thus highlighting its critical role in I/R
injury and an important target for translation. Moreover, the
cardioprotective effect of MAM was achieved at both 16 and
1.6 mg/kg, much lower concentrations than required by DMM.
Despite not changing the potency of the SDH inhibitor, the
extent of delivery of the active compound is critical. By en-
abling a large reduction in the total dose to be delivered by
using MAM, this also not only aids in avoiding side effects
but also means an appropriate dose could be delivered to large
animals and humans. As large infusion volumes for MI patients
are unfavourable, the lower concentration of MAM required
would also enable delivery of malonate in a minimal volume.
Whilst the malonate levels in the heart that led to
cardioprotection in vivo were not measured, the protection is
dependent on the levels of malonate delivered to the tissue.
When the lowest dose of MAM (1.6 mg/kg) was infused over
an extended period of time during reperfusion, this was not
protective (data not shown). Due to the rapid hydrolysis and
clearance of malonate from MAM, this will have led to a
lower concentration of malonate achieved in the heart tissue,
at a level where SDH is not efficiently inhibited. Therefore,
this suggests that the cardioprotective effect of MAM is de-
pendent on the level of malonate delivered to the heart.
Overall, more extensive studies on the malonate levels in the
heart at reperfusion and long-term protection are warranted to
confirm its translational potential.
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Conclusion
Targeting SDH in ameliorating I/R injury has gained interest
due to its mechanistic importance in both succinate accumu-
lation during ischemia and subsequent oxidation upon reper-
fusion. Whilst DMM has been shown to inhibit the accumu-
lation of succinate and prevent I/R injury in vivo, it was inef-
fective when administered at reperfusion, where clinically, it
is of interest due to the appeal of concurrent administration
with PPCI. Here, we screened a range of malonate ester
prodrugs and found that caging malonate within an improved
esterase substrate such as MAM led to significantly improved
malonate delivery both in vitro and in vivo. Moreover, MAM
also provided cardioprotection when administered at reperfu-
sion; thus, we have developed a clinically relevant therapeutic
that could be administered to MI patients during PPCI.
However, considerably more work will be required to assess
how well MAM protects the heart from the long-term cardiac
dysfunction and scarring caused by IR injury.
Furthermore, by expanding the palette of malonate esters
available, the correct malonate-based therapeutic for the
ischemia-related pathology can be chosen. Whilst MAM may
be optimal forMI, other esters that release malonate more slow-
ly may be more optimal for use in instances such as organ
transplantation, where the treatment window is predictable and
extended. Overall, the development of SDH-targeted therapeu-
tics presents a promising strategy for the treatment of I/R injury.
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